Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
> 32 33 32 33 O
1000 34 38 34 38 B-lower_bound
/ 38 39 38 39 I-lower_bound
mm^3 39 43 39 43 I-lower_bound

Any 0 3 44 47 O
corticosteroid 4 18 48 62 B-treatment
therapy 19 26 63 70 I-treatment
for 27 30 71 74 O
indications 31 42 75 86 O
other 43 48 87 92 O
than 49 53 93 97 O
cGvHD 54 59 98 103 B-clinical_variable
at 60 62 104 106 O
doses 63 68 107 112 O
> 69 70 113 114 O
1 71 72 115 116 B-lower_bound
mg 73 75 117 119 I-lower_bound
/ 75 76 119 120 I-lower_bound
kg 76 78 120 122 I-lower_bound
/ 78 79 122 123 I-lower_bound
day 79 82 123 126 I-lower_bound
methylprednisolone 83 101 127 145 B-treatment
or 102 104 146 148 O
equivalent 105 115 149 159 O
within 116 122 160 166 O
7 123 124 167 168 B-upper_bound
days 125 129 169 173 I-upper_bound
of 130 132 174 176 O
Cycle 133 138 177 182 O
1 139 140 183 184 O
Day 141 144 185 188 O
1 145 146 189 190 O

At 0 2 191 193 O
least 3 8 194 199 O
one 9 12 200 203 B-lower_bound
organ 13 18 204 209 O
( 19 20 210 211 O
not 20 23 211 214 O
lung 24 28 215 219 O
) 28 29 219 220 O
with 30 34 221 225 O
a 35 36 226 227 O
score 37 42 228 233 O
of 43 45 234 236 O
2 46 47 237 238 O
, 47 48 238 239 O
3 49 50 240 241 O
or 51 53 242 244 O
more 54 58 245 249 O
organs 59 65 250 256 O
involved 66 74 257 265 O
with 75 79 266 270 O
a 80 81 271 272 O
score 82 87 273 278 O
of 88 90 279 281 O
1 91 92 282 283 O
in 93 95 284 286 O
each 96 100 287 291 O
organ 101 106 292 297 O
, 106 107 297 298 O
or 108 110 299 301 O
lung 111 115 302 306 O
score 116 121 307 312 O
of 122 124 313 315 O
1 125 126 316 317 O

Disease 0 7 318 325 O
persistence 8 19 326 337 O
without 20 27 338 345 O
improvement 28 39 346 357 O
despite 40 47 358 365 O
continued 48 57 366 375 O
treatment 58 67 376 385 B-treatment
with 68 72 386 390 O
prednisone 73 83 391 401 B-treatment
at 84 86 402 404 O
> 87 88 405 406 O
0.5 89 92 407 410 B-lower_bound
mg 93 95 411 413 I-lower_bound
/ 95 96 413 414 I-lower_bound
kg 96 98 414 416 I-lower_bound
/ 98 99 416 417 I-lower_bound
day 99 102 417 420 I-lower_bound
or 103 105 421 423 O
1 106 107 424 425 B-lower_bound
mg 108 110 426 428 I-lower_bound
/ 110 111 428 429 I-lower_bound
kg 111 113 429 431 I-lower_bound
/ 113 114 431 432 I-lower_bound
every 114 119 432 437 I-lower_bound
other 120 125 438 443 I-lower_bound
day 126 129 444 447 I-lower_bound
for 130 133 448 451 O
at 134 136 452 454 O
least 137 142 455 460 O
4 143 144 461 462 B-lower_bound
weeks 145 150 463 468 I-lower_bound

Failed 0 6 469 475 O
prior 7 12 476 481 B-treatment
alloSCT 13 20 482 489 I-treatment
within 21 27 490 496 O
the 28 31 497 500 O
past 32 36 501 505 B-upper_bound
6 37 38 506 507 I-upper_bound
months 39 45 508 514 I-upper_bound
from 46 50 515 519 O
Cycle 51 56 520 525 O
1 57 58 526 527 O
Day 59 62 528 531 O
1 63 64 532 533 O

Have 0 4 534 538 O
undergone 5 14 539 548 O
allogeneic 15 25 549 559 B-treatment
stem 26 30 560 564 I-treatment
cell 31 35 565 569 I-treatment
transplantation 36 51 570 585 I-treatment
( 52 53 586 587 I-treatment
alloSCT 53 60 587 594 I-treatment
) 60 61 594 595 I-treatment
from 62 66 596 600 O
any 67 70 601 604 O
donor 71 76 605 610 O
source 77 83 611 617 O
( 84 85 618 619 O
matched 85 92 619 626 O
unrelated 93 102 627 636 O
donor 103 108 637 642 O
, 108 109 642 643 O
sibling 110 117 644 651 O
, 117 118 651 652 O
haplo 119 124 653 658 O
- 124 125 658 659 O
identical 125 134 659 668 O
) 134 135 668 669 O
using 136 141 670 675 O
bone 142 146 676 680 O
marrow 147 153 681 687 O
, 153 154 687 688 O
peripheral 155 165 689 699 O
blood 166 171 700 705 O
stem 172 176 706 710 O
cells 177 182 711 716 O
, 182 183 716 717 O
or 184 186 718 720 O
cord 187 191 721 725 O
blood 192 197 726 731 O

Participants 0 12 732 744 O
with 13 17 745 749 O
clinically 18 28 750 760 O
diagnosed 29 38 761 770 O
moderate 39 47 771 779 O
to 48 50 780 782 O
severe 51 57 783 789 B-chronic_disease
cGvHD 58 63 790 795 I-chronic_disease
according 64 73 796 805 O
to 74 76 806 808 O
NIH 77 80 809 812 O
Consensus 81 90 813 822 O
Criteria 91 99 823 831 O
prior 100 105 832 837 O
to 106 108 838 840 O
randomization 109 122 841 854 O

Participants 0 12 855 867 O
with 13 17 868 872 O
relapsed 18 26 873 881 O
primary 27 34 882 889 B-cancer
malignancy 35 45 890 900 I-cancer

Patients 0 8 901 909 O
receiving 9 18 910 919 O
up 19 21 920 922 O
to 22 24 923 925 O
30 25 27 926 928 B-upper_bound
mg 28 30 929 931 I-upper_bound
by 31 33 932 934 O
mouth 34 39 935 940 O
once 40 44 941 945 O
a 45 46 946 947 O
day 47 50 948 951 O
of 51 53 952 954 O
hydrocortisone 54 68 955 969 B-treatment
( 69 70 970 971 O
i.e. 70 74 971 975 O
, 74 75 975 976 O
physiologic 76 87 977 988 O
replacement 88 99 989 1000 O
dose 100 104 1001 1005 O
) 104 105 1005 1006 O
of 106 108 1007 1009 O
corticosteroids 109 124 1010 1025 B-treatment

Patients 0 8 1026 1034 O
that 9 13 1035 1039 O
transition 14 24 1040 1050 O
from 25 29 1051 1055 O
active 30 36 1056 1062 O
aGvHD 37 42 1063 1068 B-chronic_disease
to 43 45 1069 1071 O
cGvHD 46 51 1072 1077 B-chronic_disease
without 52 59 1078 1085 O
tapering 60 68 1086 1094 O
off 69 72 1095 1098 O
corticosteroids 73 88 1099 1114 B-treatment
Â± 89 90 1115 1116 I-treatment
CNI 91 94 1117 1120 I-treatment
and 95 98 1121 1124 O
any 99 102 1125 1128 O
systemic 103 111 1129 1137 O
treatment 112 121 1138 1147 B-treatment

Severe 0 6 1148 1154 B-chronic_disease
cGvHD 7 12 1155 1160 I-chronic_disease

Steroid 0 7 1161 1168 B-treatment
refractory 8 18 1169 1179 O
cGvHD 19 24 1180 1185 B-chronic_disease
occurring 25 34 1186 1195 O
after 35 40 1196 1201 O
a 41 42 1202 1203 O
non 43 46 1204 1207 O
- 46 47 1207 1208 O
scheduled 47 56 1208 1217 O
donor 57 62 1218 1223 B-treatment
lymphocyte 63 73 1224 1234 I-treatment
infusion 74 82 1235 1243 I-treatment
( 83 84 1244 1245 I-treatment
DLI 84 87 1245 1248 I-treatment
) 87 88 1248 1249 I-treatment
administered 89 101 1250 1262 O
for 102 105 1263 1266 O
preemptive 106 116 1267 1277 B-treatment
treatment 117 126 1278 1287 I-treatment
of 127 129 1288 1290 O
malignancy 130 140 1291 1301 B-cancer
recurrence 141 151 1302 1312 O

currently 0 9 1313 1322 O
receiving 10 19 1323 1332 O
systemic 20 28 1333 1341 B-treatment
or 29 31 1342 1344 I-treatment
topical 32 39 1345 1352 I-treatment
corticosteroids 40 55 1353 1368 I-treatment
for 56 59 1369 1372 O
the 60 63 1373 1376 O
treatment 64 73 1377 1386 O
of 74 76 1387 1389 O
cGvHD 77 82 1390 1395 B-chronic_disease
for 83 86 1396 1399 O
a 87 88 1400 1401 O
duration 89 97 1402 1410 O
of 98 100 1411 1413 O
< 101 102 1414 1415 O
12 103 105 1416 1418 B-upper_bound
months 106 112 1419 1425 I-upper_bound
prior 113 118 1426 1431 I-upper_bound
to 119 121 1432 1434 O
Cycle 122 127 1435 1440 O
1 128 129 1441 1442 O
Day 130 133 1443 1446 O
1 134 135 1447 1448 O
( 136 137 1449 1450 O
if 137 139 1450 1452 O
applicable 140 150 1453 1463 O
) 150 151 1463 1464 O

must 0 4 1465 1469 O
accept 5 11 1470 1476 O
to 12 14 1477 1479 O
be 15 17 1480 1482 O
treated 18 25 1483 1490 O
with 26 30 1491 1495 O
only 31 35 1496 1500 O
one 36 39 1501 1504 O
of 40 42 1505 1507 O
the 43 46 1508 1511 O
following 47 56 1512 1521 O
BAT 57 60 1522 1525 O
options 61 68 1526 1533 O
on 69 71 1534 1536 O
Cycle 72 77 1537 1542 O
1 78 79 1543 1544 O
Day 80 83 1545 1548 O
1 84 85 1549 1550 O
( 86 87 1551 1552 O
additions 87 96 1552 1561 O
and 97 100 1562 1565 O
changes 101 108 1566 1573 O
are 109 112 1574 1577 O
allowed 113 120 1578 1585 O
during 121 127 1586 1592 O
the 128 131 1593 1596 O
course 132 138 1597 1603 O
of 139 141 1604 1606 O
the 142 145 1607 1610 O
study 146 151 1611 1616 O
, 151 152 1616 1617 O
but 153 156 1618 1621 O
only 157 161 1622 1626 O
with 162 166 1627 1631 O
BAT 167 170 1632 1635 O
from 171 175 1636 1640 O
the 176 179 1641 1644 O
following 180 189 1645 1654 O
BAT 190 193 1655 1658 O
options 194 201 1659 1666 O
): 201 203 1666 1668 O
extracorporeal 204 218 1669 1683 B-treatment
photopheresis 219 232 1684 1697 I-treatment
( 233 234 1698 1699 I-treatment
ECP 234 237 1699 1702 I-treatment
) 237 238 1702 1703 I-treatment
, 238 239 1703 1704 O
low 240 243 1705 1708 O
- 243 244 1708 1709 O
dose 244 248 1709 1713 O
methotrexate 249 261 1714 1726 B-treatment
( 262 263 1727 1728 I-treatment
MTX 263 266 1728 1731 I-treatment
) 266 267 1731 1732 I-treatment
, 267 268 1732 1733 O
mycophenolate 269 282 1734 1747 B-treatment
mofetil 283 290 1748 1755 I-treatment
( 291 292 1756 1757 I-treatment
MMF 292 295 1757 1760 I-treatment
) 295 296 1760 1761 I-treatment
, 296 297 1761 1762 O
mTOR 298 302 1763 1767 B-treatment
inhibitors 303 313 1768 1778 I-treatment
( 314 315 1779 1780 I-treatment
everolimus 315 325 1780 1790 I-treatment
or 326 328 1791 1793 I-treatment
sirolimus 329 338 1794 1803 I-treatment
) 338 339 1803 1804 I-treatment
, 339 340 1804 1805 O
infliximab 341 351 1806 1816 B-treatment
, 351 352 1816 1817 O
rituximab 353 362 1818 1827 B-treatment
, 362 363 1827 1828 O
pentostatin 364 375 1829 1840 B-treatment
, 375 376 1840 1841 O
imatinib 377 385 1842 1850 B-treatment
, 385 386 1850 1851 O
ibrutinib 387 396 1852 1861 B-treatment

participant 0 11 1862 1873 O
achieved 12 20 1874 1882 O
complete 21 29 1883 1891 O
or 30 32 1892 1894 O
partial 33 40 1895 1902 O
response 41 49 1903 1911 O
and 50 53 1912 1915 O
has 54 57 1916 1919 O
been 58 62 1920 1924 O
off 63 66 1925 1928 O
JAK 67 70 1929 1932 B-treatment
inhibitor 71 80 1933 1942 I-treatment
treatment 81 90 1943 1952 I-treatment
for 91 94 1953 1956 O
at 95 97 1957 1959 O
least 98 103 1960 1965 O
8 104 105 1966 1967 B-lower_bound
weeks 106 111 1968 1973 I-lower_bound
prior 112 117 1974 1979 I-lower_bound
to 118 120 1980 1982 O
Cycle 121 126 1983 1988 O
1 127 128 1989 1990 O
Day 129 132 1991 1994 O
1 133 134 1995 1996 O

platelet 0 8 1997 2005 B-clinical_variable
count 9 14 2006 2011 I-clinical_variable
> 15 16 2012 2013 O
25,000/ 17 24 2014 2021 B-lower_bound
mm^3 25 29 2022 2026 I-lower_bound

who 0 3 2027 2030 O
have 4 8 2031 2035 O
received 9 17 2036 2044 O
2 18 19 2045 2046 B-lower_bound
or 20 22 2047 2049 O
more 23 27 2050 2054 O
systemic 28 36 2055 2063 B-treatment
treatment 37 46 2064 2073 I-treatment
for 47 50 2074 2077 O
cGvHD 51 56 2078 2083 B-chronic_disease
in 57 59 2084 2086 O
addition 60 68 2087 2095 O
to 69 71 2096 2098 O
corticosteroids 72 87 2099 2114 B-treatment
Â± 88 89 2115 2116 O
CNI 90 93 2117 2120 B-treatment
for 94 97 2121 2124 O
cGvHD 98 103 2125 2130 O

who 0 3 2131 2134 O
have 4 8 2135 2139 O
received 9 17 2140 2148 O
a 18 19 2149 2150 O
scheduled 20 29 2151 2160 O
DLI 30 33 2161 2164 B-treatment
as 34 36 2165 2167 O
part 37 41 2168 2172 O
of 42 44 2173 2175 O
their 45 50 2176 2181 O
transplant 51 61 2182 2192 B-treatment
procedure 62 71 2193 2202 I-treatment
and 72 75 2203 2206 O
not 76 79 2207 2210 O
for 80 83 2211 2214 O
management 84 94 2215 2225 O
of 95 97 2226 2228 O
malignancy 98 108 2229 2239 B-cancer
relapse 109 116 2240 2247 O

who 0 3 2248 2251 O
were 4 8 2252 2256 O
treated 9 16 2257 2264 O
with 17 21 2265 2269 O
prior 22 27 2270 2275 O
JAK 28 31 2276 2279 B-treatment
inhibitors 32 42 2280 2290 I-treatment
for 43 46 2291 2294 O
aGvHD 47 52 2295 2300 B-chronic_disease

